Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for the project: “Protein Pathway Activation Based Signaling Mapping of Head And Neck Cancers.”
CAPMM researchers will receive laser microdissected tumour samples from banked Formalin-Fixed Paraffin-Embedded (FFPE) clinical biopsy samples from patients with HPV‐positive head and neck cancers who were treated for newly diagnosed disease.
The researchers will utilize comprehensive reverse‐phase protein microarray (RPPA)-based analysis of 170 pre‐specified proteins and phosphoproteins involved in inflammation pathways, DNA damage and repair pathways, reactive oxygen species pathways, mitophagy pathways, cell survival and apoptosis pathways.
Petricoin received $63,640 from Inova Healthcare for this research. Funding began in May 2024 and will end in May 2025.
Source: George Mason University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.